GlassScriptPhysician profile
Barry J Jacobson
NPI 1275679250
$301,860.98
in general payments reported to CMS, 2019-2025
26 companies · $19K in 2025
The $19K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166K · 2020: $19K · 2021: $33K · 2022: $21K · 2023: $18K · 2024: $26K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $44K · Travel and Lodging: $12K · Food and Beverage: $6,232 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44,400.00 |
| Travel and Lodging | $12,168.03 |
| Food and Beverage | $6,232.04 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $223,959.49 | 2019-2025 | Evenity, Prolia, Prolia |
| Radius Health, INC. | $75,990.66 | 2019-2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $495.97 | 2019-2025 | Strensiq |
| Almatica Pharma LLC | $276.10 | 2024-2025 | Teriparatide |
| Therapeuticsmd, INC. | $203.25 | 2019-2022 | |
| Abbvie INC. | $203.08 | 2019-2021 | |
| Kyowa Kirin, INC. | $144.58 | 2023 | Crysvita |
| Ucb, INC. | $101.82 | 2021-2022 | |
| Sage Therapeutics, LLC | $68.34 | 2025 | Zurzuvae |
| Ultragenyx Pharmaceutical INC. | $51.93 | 2019-2022 | |
| Alvogen INC | $45.19 | 2024-2025 | Teriparatide |
| Millicent US INC | $43.86 | 2019 | |
| Lilly USA, LLC | $33.83 | 2020-2021 | |
| Ascendis Pharma Endocrinology INC | $30.11 | 2025 | Yorvipath |
| Ipsen Biopharmaceuticals, INC | $29.52 | 2023 | Sohonos |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $22.94 | 2024 | |
| Hologic Sales and Service, LLC | $20.67 | 2024 | Aptima |
| Kaleo, INC. | $19.07 | 2019 | |
| Sumitomo Pharma America, INC. | $18.93 | 2025 | Myfembree |
| Agile Therapeutics, INC. | $18.72 | 2021 | |
| Ascend Therapeutics US, LLC | $18.00 | 2021 | |
| Xeris Pharmaceuticals, INC. | $16.48 | 2024 | Gvoke Hypopen |
| Mylan Pharmaceuticals INC. | $13.16 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.77 | 2019 | |
| Novo Nordisk INC | $11.51 | 2019 | |
| Exeltis, USA INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Jacobson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.